Hemindermeet Singh, MD
Cardiovascular Disease · Perrysburg, OHNPI 1821345695
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,355 and has fallen 89.8% since, to $341 in 2025.
Across 255 payments — averaging $34.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Abbott$1K
- Esperion Therapeutics, Inc.$589
- Johnson & Johnson$505
- Boehringer Ingelheim$437
- Inari Medical, Inc.$399
- plus $4K from 29 others
Across 193 payments — averaging $1487.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$138K
- Boehringer Ingelheim International GmbH$40K
- Medtronic$31K
- Impulse Dynamics (USA) Inc.$25K
- Biotronik Inc.$25K
- Elutia, Inc.$16K
- plus $12K from 2 others
What the payments were for
- Travel & lodging$5867%
- Food & beverage$8,11092%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $1,415 |
| Abbott | 19 | $1,406 |
| Esperion Therapeutics, Inc. | 14 | $589 |
| Johnson & Johnson | 28 | $505 |
| Boehringer Ingelheim | 13 | $437 |
| Inari Medical, Inc. | 6 | $399 |
| AstraZeneca | 16 | $380 |
| Novartis | 23 | $376 |
| Merck | 18 | $362 |
| Shockwave Medical, Inc | 5 | $347 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $280 |
| Atricure, Inc. | 9 | $273 |
| Abiomed | 5 | $243 |
| Amgen | 8 | $226 |
| Pfizer | 9 | $218 |
| Kestra Medical Technology Services, Inc. | 2 | $189 |
| Amarin Pharma, Inc. | 12 | $180 |
| Cardiovascular Systems Inc. | 3 | $159 |
| Impulse Dynamics (USA) Inc. | 1 | $151 |
| Penumbra, Inc. | 1 | $142 |
| Astellas Pharma US Inc | 2 | $114 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $79 |
| Collegium Pharmaceutical, Inc. | 5 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Lundbeck LLC | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Bioventus LLC | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUPERA$576
- OPTIMIZER$302
- FLOWTRIEVER CATHETER, S$262
- CT THROMBECTOMY SYSTEM KIT$262
- NEXLIZET$250
- NEXLETOL$250
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$250
- OPTIS$190
- ONYX FRONTIER$159
- Optis Coronary Imaging System$144
- Indigo System$142
- Coronary Orbital Atherectomy System$136
- Xience Sierra Coronary Stent System$136
- LifeVest$131
- Impella$129
- Assure WCD$110
- JARDIANCE$110
- XARELTO$100
How this compares
$8,824 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 224 | $257,140 |
| EntrestoSacubitril/Valsartan | 91 | $85,060 |
| XareltoRivaroxaban | 80 | $84,279 |
| BrilintaTicagrelor | 73 | $45,811 |
| FarxigaDapagliflozin Propanediol | 23 | $23,418 |
| Repatha SureclickEvolocumab | 39 | $21,130 |
| JardianceEmpagliflozin | 22 | $20,928 |
| Metoprolol Succinate | 398 | $4,341 |
| ClopidogrelClopidogrel Bisulfate | 337 | $3,965 |
| Atorvastatin Calcium | 298 | $3,268 |
| Propafenone Hcl | 35 | $2,430 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 97 | $2,134 |
| Ranolazine ErRanolazine | 36 | $2,062 |
| Metoprolol Tartrate | 245 | $1,922 |
| Amiodarone Hcl | 89 | $1,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $218 | $257,140224 claims |
| NovartisEntresto | $376 | $85,06091 claims |
| Johnson & JohnsonXarelto | $505 | $84,27980 claims |
| AstraZenecaBrilinta, Farxiga | $380 | $69,22996 claims |
| Boehringer IngelheimJardiance | $437 | $20,92822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Perrysburg
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.